Abstract
Expansion of polyglutamine (polyQ) sequence in some proteins leads to their aggregation, which is responsible for neurodegenerative diseases like Huntington’s disease, ataxia etc. A flanking domain is usually fused at the N-terminal to polyQ in these proteins. On linking the flanking residues to polyQ, they accelerate aggregation of the proteins, which initiates from the flanking residues. In this report the inherent propensity of the flanking residues towards aggregation in six aggregating proteins has been elucidated from their primary sequences with the help of Betascan and PASTA programs and explored unambiguously. This will provide a molecular mechanism of this process. Suppression of aggregation using chaperones like αB-crystallin by masking the exposed hydrophobic surface of flanking residues is also documented through molecular docking, which could be applied for inhibition of aggregation of this type of proteins.
Keywords: PolyQ aggregation, flanking residues, chaperone
Protein & Peptide Letters
Title:Inherent Aggregation Propensity of Flanking Residues Attached to Polyglutamines: Implication to Aggregation Inhibition
Volume: 20 Issue: 5
Author(s): Kalyan Sundar Ghosh
Affiliation:
Keywords: PolyQ aggregation, flanking residues, chaperone
Abstract: Expansion of polyglutamine (polyQ) sequence in some proteins leads to their aggregation, which is responsible for neurodegenerative diseases like Huntington’s disease, ataxia etc. A flanking domain is usually fused at the N-terminal to polyQ in these proteins. On linking the flanking residues to polyQ, they accelerate aggregation of the proteins, which initiates from the flanking residues. In this report the inherent propensity of the flanking residues towards aggregation in six aggregating proteins has been elucidated from their primary sequences with the help of Betascan and PASTA programs and explored unambiguously. This will provide a molecular mechanism of this process. Suppression of aggregation using chaperones like αB-crystallin by masking the exposed hydrophobic surface of flanking residues is also documented through molecular docking, which could be applied for inhibition of aggregation of this type of proteins.
Export Options
About this article
Cite this article as:
Sundar Ghosh Kalyan, Inherent Aggregation Propensity of Flanking Residues Attached to Polyglutamines: Implication to Aggregation Inhibition, Protein & Peptide Letters 2013; 20 (5) . https://dx.doi.org/10.2174/0929866511320050010
DOI https://dx.doi.org/10.2174/0929866511320050010 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Heme Oxygenase-1 as a Therapeutic Target in Neurodegenerative Diseases and Brain Infections
Current Pharmaceutical Design Identification of Electrophysiological Changes in Alzheimer's Disease: A Microarray Based Transcriptomics and Molecular Pathway Analysis Study
CNS & Neurological Disorders - Drug Targets Selective Acetyl- and Butyrylcholinesterase Inhibitors Reduce Amyloid-β Ex Vivo Activation of Peripheral Chemo-cytokines From Alzheimer's Disease Subjects: Exploring the Cholinergic Anti-inflammatory Pathway
Current Alzheimer Research Meet Our Editorial Board Member
Current Aging Science Mitochondrial Biogenesis: A Therapeutic Target for Neurodevelopmental Disorders and Neurodegenerative Diseases
Current Pharmaceutical Design The Design of Vectors for RNAi Delivery System
Current Pharmaceutical Design Efficacy of Vitamins B Supplementation on Mild Cognitive Impairment and Alzheimer`s Disease: A Systematic Review and Meta-Analysis
Current Alzheimer Research Therapeutic Targets in Prostaglandin E2 Signaling for Neurologic Disease
Current Medicinal Chemistry Reduction of Oxidative/Nitrosative Stress in Brain and its Involvement in the Neuroprotective Effect of n-3 PUFA in Alzheimer’s Disease
Current Alzheimer Research A Systematic Review of Drugs in Late-Stage Development for the Treatment of Multiple Sclerosis: A Focus on Oral Synthetic Drugs
Inflammation & Allergy - Drug Targets (Discontinued) Evaluation and Prediction of Early Alzheimer’s Disease Using a Machine Learning-based Optimized Combination-Feature Set on Gray Matter Volume and Quantitative Susceptibility Mapping
Current Alzheimer Research Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance
Current Neuropharmacology Treatment of Alzheimer's Disease: Classical Therapeutic Approach
Current Pharmaceutical Analysis The Application of Mass Spectrometry to Proteomics and Metabolomics in Biomarker Discovery and Drug Development
Current Molecular Pharmacology Histone Deacetylase (HDAC) Inhibitors as Potential Drugs to Target Memory and Adult Hippocampal Neurogenesis
Current Psychopharmacology Glycogen Metabolism and Brain Pathologies
Central Nervous System Agents in Medicinal Chemistry Nonhuman Primate Models of Alzheimer-Like Cerebral Proteopathy
Current Pharmaceutical Design Brain Slices as Models for Neurodegenerative Disease and Screening Platforms to Identify Novel Therapeutics
Current Neuropharmacology The Interplay between G-quadruplex and Transcription
Current Medicinal Chemistry Role of Phytomolecules in the Treatment of Obesity: Targets, Mechanisms and Limitations
Current Topics in Medicinal Chemistry